Novo has bought three early-stage obesity programs from Kallyope, adding non-incretin assets to a pipeline still anchored by semaglutide and other metabolic drugs.
Jacob Petersen, Novo’s head of global research, said the programs are not incretins, the gut-hormone class that includes GLP-1s. He described the additions as a “potential first-in-class peptide,” a “follow-on small molecule” for a novel target, and a “small molecule receptor agonist.” Novo did not disclose financial terms or the drug targets.
The pipeline signal
The immediate strategic read is that Novo is looking beyond the mechanism that built its obesity franchise. As obesity treatment expands, large companies need more than another GLP-1 to differentiate future products, especially if they want options that can address different patient needs or combination strategies.
Tamara Darrow, Novo’s head of global business development, said the company is adding “promising externally grown science” and using outside opportunities to strengthen and differentiate its pipeline. Petersen also said Novo expects multiple candidates to enter clinical development this year as it builds a broader set of treatment approaches for people living with obesity.
One of the programs may be K-554, which Kallyope described in January as a “novel, once weekly, non-incretin approach to regulating food intake” that works through biology different from GLP-1s. At that time, Kallyope said it was working to start phase 1 testing and expected data in the second half of 2026. The asset is not currently listed on Kallyope’s pipeline, and no clinical trials run by the company are listed on the federal trial database.
The road here
Novo and Kallyope have worked together before, but a Novo spokesperson said this transaction is new. The deal also arrives one day after Novo announced a $1.4 billion biobucks pact with Orbis Medicines to develop macrocycle drugs aimed at “high-value” cardiometabolic targets.
The acquisitions come during a broader reset at the Danish drugmaker, which recently refreshed its brand by dropping “Nordisk” from everyday use. They also follow a setback outside the company’s core metabolic focus: Novo recently abandoned two more phase 3 trials of ziltivekimab in heart failure after the drug had already failed in phase 3 in atherosclerotic cardiovascular disease, chronic kidney disease and inflammation. Analysts had previously projected peak sales of around $3 billion for ziltivekimab.
That context makes the Kallyope buy look less like a one-off bolt-on and more like a return to Novo’s stated center of gravity. CEO Mike Doustdar recently said obesity and diabetes remain “very core to what we do.”
